Krystal Biotech, Inc. (KRYS) on Decifer

Decifer ranks KRYS number 184 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 34% a year, faster than 83 in 100 companies we measure.
• It keeps about 49 cents of every sales dollar as cash, safer than 98 in 100 companies we measure.
• It earns about 14% a year on the money put into the business, better than 71 in 100 companies we measure.
• It costs about 41 times its yearly profit; the middle of its industry is 25. Cheaper than 23 in 100 companies we measure, against their own industries.

The current read

The evidence on KRYS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full KRYS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.